Seres Therapeutics Inc (MCRB)

$0.7427

+0.01

(+1.81%)▲

Market is closed - opens 7 PM, 26 Apr 2024

Insights on Seres Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 126.47M → 64.0K (in $), with an average decrease of 89.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -47.85M → -41.24M (in $), with an average increase of 16.0% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 52.5% return, outperforming this stock by 140.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 239.5% return, outperforming this stock by 336.0%

Performance

  • $0.70
    $0.83
    $0.74
    downward going graph

    5.38%

    Downside

    Day's Volatility :15.17%

    Upside

    10.35%

    downward going graph
  • $0.54
    $6.65
    $0.74
    downward going graph

    27.03%

    Downside

    52 Weeks Volatility :91.88%

    Upside

    88.87%

    downward going graph

Returns

PeriodSeres Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-35.42%
0.5%
0.0%
6 Months
-50.15%
11.7%
0.0%
1 Year
-88.4%
6.2%
2.2%
3 Years
-96.53%
13.5%
-23.0%

Highlights

Market Capitalization
109.6M
Book Value
- $0.33
Earnings Per Share (EPS)
-0.89
PEG Ratio
-0.11
Wall Street Target Price
7.22
Profit Margin
-90.03%
Operating Margin TTM
-61759.38%
Return On Assets TTM
-19.08%
Return On Equity TTM
-538.57%
Revenue TTM
126.3M
Revenue Per Share TTM
0.99
Quarterly Revenue Growth YOY
-93.4%
Gross Profit TTM
-165.8M
EBITDA
-101.7M
Diluted Eps TTM
-0.89
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.14
EPS Estimate Next Year
-0.8
EPS Estimate Current Quarter
-0.5
EPS Estimate Next Quarter
-0.35

Analyst Recommendation

Buy
    76%Buy
    15%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Seres Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 872.13%

Current $0.74
Target $7.22

Company Financials

FY18Y/Y Change
Revenue
28.3M
↓ 11.94%
Net Income
-98.9M
↑ 10.7%
Net Profit Margin
-350.03%
↓ 71.59%
FY19Y/Y Change
Revenue
34.5M
↑ 22.07%
Net Income
-64.2M
↓ 35.07%
Net Profit Margin
-186.19%
↑ 163.84%
FY20Y/Y Change
Revenue
33.2M
↓ 3.74%
Net Income
-86.5M
↑ 34.57%
Net Profit Margin
-260.29%
↓ 74.1%
FY21Y/Y Change
Revenue
144.9M
↑ 336.33%
Net Income
-61.5M
↓ 28.87%
Net Profit Margin
-42.43%
↑ 217.86%
FY22Y/Y Change
Revenue
7.1M
↓ 95.08%
Net Income
-253.8M
↑ 312.75%
Net Profit Margin
-3.6K%
↓ 3518.51%
FY23Y/Y Change
Revenue
126.3M
↑ 1672.24%
Net Income
-113.7M
↓ 55.2%
Net Profit Margin
-90.02%
↑ 3470.92%
Q3 FY22Q/Q Change
Revenue
3.4M
↑ 183.22%
Net Income
-60.9M
↓ 7.93%
Net Profit Margin
-1.8K%
↑ 3671.35%
Q4 FY22Q/Q Change
Revenue
975.0K
↓ 71.69%
Net Income
-69.3M
↑ 13.77%
Net Profit Margin
-7.1K%
↓ 5337.94%
Q1 FY23Q/Q Change
Revenue
-522.0K
↓ 153.54%
Net Income
-71.8M
↑ 3.6%
Net Profit Margin
13.8K%
↑ 20857.11%
Q2 FY23Q/Q Change
Revenue
126.5M
↓ 24328.54%
Net Income
46.6M
↓ 164.85%
Net Profit Margin
36.81%
↓ 13714.15%
Q3 FY23Q/Q Change
Revenue
310.0K
↓ 99.75%
Net Income
-47.9M
↓ 202.8%
Net Profit Margin
-15.4K%
↓ 15473.58%
Q4 FY23Q/Q Change
Revenue
64.0K
↓ 79.35%
Net Income
-41.2M
↓ 13.8%
Net Profit Margin
-64.5K%
↓ 49013.23%
FY18Y/Y Change
Total Assets
120.5M
↓ 36.43%
Total Liabilities
168.5M
↑ 30.81%
FY19Y/Y Change
Total Assets
132.4M
↑ 9.93%
Total Liabilities
180.8M
↑ 7.27%
FY20Y/Y Change
Total Assets
342.9M
↑ 158.94%
Total Liabilities
168.2M
↓ 6.96%
FY21Y/Y Change
Total Assets
354.9M
↑ 3.48%
Total Liabilities
223.4M
↑ 32.8%
FY22Y/Y Change
Total Assets
348.8M
↓ 1.71%
Total Liabilities
338.0M
↑ 51.33%
FY23Y/Y Change
Total Assets
358.6M
↑ 2.81%
Total Liabilities
403.5M
↑ 19.37%
Q3 FY22Q/Q Change
Total Assets
311.9M
↑ 14.16%
Total Liabilities
244.3M
↓ 2.34%
Q4 FY22Q/Q Change
Total Assets
348.8M
↑ 11.84%
Total Liabilities
338.0M
↑ 38.36%
Q1 FY23Q/Q Change
Total Assets
270.2M
↓ 22.53%
Total Liabilities
318.1M
↓ 5.9%
Q2 FY23Q/Q Change
Total Assets
406.4M
↑ 50.41%
Total Liabilities
383.8M
↑ 20.66%
Q3 FY23Q/Q Change
Total Assets
367.7M
↓ 9.52%
Total Liabilities
382.8M
↓ 0.25%
Q4 FY23Q/Q Change
Total Assets
358.6M
↓ 2.47%
Total Liabilities
403.5M
↑ 5.39%
FY18Y/Y Change
Operating Cash Flow
-62.9M
↓ 16.78%
Investing Cash Flow
112.3M
↑ 97.09%
Financing Cash Flow
268.0K
↑ 222.89%
FY19Y/Y Change
Operating Cash Flow
-76.5M
↑ 21.74%
Investing Cash Flow
-30.5M
↓ 127.17%
Financing Cash Flow
86.2M
↑ 32075.75%
FY20Y/Y Change
Operating Cash Flow
-93.6M
↑ 22.33%
Investing Cash Flow
-158.9M
↑ 420.65%
Financing Cash Flow
303.4M
↑ 251.87%
FY21Y/Y Change
Operating Cash Flow
6.7M
↓ 107.14%
Investing Cash Flow
64.1M
↓ 140.33%
Financing Cash Flow
1.2M
↓ 99.61%
FY22Y/Y Change
Operating Cash Flow
-228.8M
↓ 3521.29%
Investing Cash Flow
82.4M
↑ 28.62%
Financing Cash Flow
129.6M
↑ 10901.87%
Q3 FY22Q/Q Change
Operating Cash Flow
-59.6M
↑ 19.41%
Investing Cash Flow
40.1M
↑ 71.51%
Financing Cash Flow
98.0M
↑ 75305.38%
Q4 FY22Q/Q Change
Operating Cash Flow
-52.9M
↓ 11.23%
Investing Cash Flow
5.9M
↓ 85.23%
Financing Cash Flow
4.6M
↓ 95.31%
Q1 FY23Q/Q Change
Operating Cash Flow
-76.6M
↑ 44.79%
Investing Cash Flow
2.7M
↓ 53.78%
Financing Cash Flow
5.7M
↑ 23.04%
Q2 FY23Q/Q Change
Operating Cash Flow
66.0M
↓ 186.16%
Investing Cash Flow
10.5M
↑ 283.97%
Financing Cash Flow
58.2M
↑ 928.59%

Technicals Summary

Sell

Neutral

Buy

Seres Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Seres Therapeutics Inc
Seres Therapeutics Inc
-1.24%
-50.15%
-88.4%
-96.53%
-89.9%
Moderna, Inc.
Moderna, Inc.
-1.15%
39.75%
-18.77%
-40.22%
304.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.56%
12.46%
14.48%
77.72%
159.17%
Novo Nordisk A/s
Novo Nordisk A/s
-2.8%
32.13%
52.48%
239.51%
414.16%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.96%
10.08%
23.01%
83.3%
130.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Seres Therapeutics Inc
Seres Therapeutics Inc
NA
NA
-0.11
-1.14
-5.39
-0.19
NA
-0.33
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Seres Therapeutics Inc
Seres Therapeutics Inc
Buy
$109.6M
-89.9%
NA
-90.03%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
304.34%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
159.17%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
414.16%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
130.08%
28.81
36.68%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    15.31%

  • FMR Inc

    12.84%

  • BlackRock Inc

    4.86%

  • Vanguard Group Inc

    3.98%

  • Hudson Bay Capital Management LP

    2.86%

  • Point72 Asset Management, L.P.

    1.82%

Corporate Announcements

  • Seres Therapeutics Inc Earnings

    Seres Therapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Organization
Seres Therapeutics Inc
Employees
233
CEO
Mr. Eric D. Shaff M.B.A.
Industry
Health Technology

Discover More

FAQs